Back

Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia

30 August 2026 (10:15 - 10:45)
Organised by: Logo
Congress Presentation Part of: New advancements in targeting atherogenic lipoproteins Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Kaloyan Dyankov

University Hospital Alexandrovska, Sofia (Bulgaria)

4 More presentations in this session

Presentation thumbnail
Long-term outcomes of beta-blockers in post-MI patients with mildly reduced or preserved left ventricular ejection fraction: a systematic review and meta-analysis
Doctor K. Hosseini (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Preclinical study and evaluation of S016, a novel oral small-molecule PCSK9 inhibitor
Doctor G. Cen (Chengdu - Sichuan, CN)
Abstract Slides
Presentation thumbnail
Efficacy of PCSK9 inhibitors in patients with peripheral artery disease: insights from the AT-TARGET-IT Registry
Doctor M. Di Santo (Naples, IT)
Abstract Slides
Presentation thumbnail
Apolipoprotein C-III inhibition reduces acute pancreatitis in familial chylomicronemia syndrome: a meta-analysis of randomized trials
Doctor K. Mahajan (Mandi, IN)

Access the full session

Session thumbnail
New advancements in targeting atherogenic lipoproteins

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Boosting secondary prevention: efficacy and adherence of inclisiran in post-acute coronary syndrome very high-risk patients
3 April 2025
thumbnail
Congress Presentation
Lipoprotein(a) and cardiovascular prognosis of familial dyslipidemias: data from a 10-year follow-up study
1 September 2024
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025
thumbnail
Congress Presentation
Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy
24 June 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources